Trials / Suspended
SuspendedNCT05961007
Evaluation of IBI302 Injection in nAMD or DME
A Dose Escalation Study to Evaluate the Safety and Tolerability of IBI302 Intravitreal Injection in Subjects With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema AND A Multi-center, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With Diabetic Macular Edema
- Status
- Suspended
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 234 (estimated)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy and safety of intravitreal IBI302 in the treatment of subjects with neovascular age-related macular degeneration (only in Phase I) or diabetic macular edema.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Intravitreal injection of IBI302(dose 1) | IBI302(dose 1) intravitreal injection given as protocol |
| BIOLOGICAL | Intravitreal injection of IBI302(dose 2) | IBI302(dose 2) intravitreal injection given as protocol |
| BIOLOGICAL | Intravitreal injection of IBI302(dose 3) | IBI302(dose 3) intravitreal injection given as protocol |
| DRUG | Intravitreal injection of Aflibercept | Aflibercept intravitreal injection given as protocol |
Timeline
- Start date
- 2021-11-18
- Primary completion
- 2023-10-31
- Completion
- 2024-04-30
- First posted
- 2023-07-27
- Last updated
- 2023-07-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05961007. Inclusion in this directory is not an endorsement.